

PATTERNS OF RESISTANCE TO ANTIBIOTICS AT KING FAHD HOSPITAL OF THE UNIVERSITY

Mastour S. Al-Ghamdi, PhD,* Fikry El-Morsy, PhD,† Zaki H. Al-Mustafa, PhD*
Departments of *Pharmacology and †Microbiology, College of Medicine, King Faisal University, Dammam, Saudi Arabia

هدف الدراسة: لوحظ مؤخرا وفي جميع أنحاء العالم ارتفاعا مطردا في نسبة مقاومة البكتيريا لمضادات الجراثيم مما قد يؤدي إلى الفشل في علاج الأحماج أو زيادة تكاليف العلاج. لذلك فإنه من الأهمية بمكان دراسة نمط مقاومة البكتيريا للأنواع المستعملة من مضادات الجراثيم بانتظام على مستوى الإقليم أو الدولة.

طريقة الدراسة: لقد تم تحليل نمط سلوك البكتيريا التي عزلت في مستشفى الملك فهد الجامعي بالخبر على مدار سنة كاملة تجاه مضادات الجراثيم المستعملة في المستشفى.

نتائج الدراسة: لقد تم عزل 3679 كائن جرثومي حي ينتمون إلى 35 نوعا وكانت أجناس البكتيريا العقدية هي الأكثر شيوعا (25.5%) يليها العنقودية الذهبية (16.1%)، الإشريكية القولونية (12.7%)، أجناس الزائفة (9.3%)، و أجناس الكيسلية (7.0%).

لقد كان أكثر من 50% من أجناس البكتيريا المعوية وكذلك المستديمة النزلية مقاوم لدواء الامبسلين ومركب الامكسيسلين + الكالونيت بينما كان نحو 60% و 38.1% من بكتيريا الإشريكية القولونية مقاوم للدواءين السابقين على التوالي. أما بالنسبة للبكتيريا العنقودية الذهبية فقد كان نحو 98.1% منها مقاوم للبنسلين فيما 91.1% مقاوم لمركب الامكسيسلين + الكالونيت و 25.5% مقاوم للمثيلين ولكنها بقيت حساسة لدواء الفنكوميسين.

لقد لوحظ مقاومة عالية لدواء التتراسيكلين (< 53% من 2830) وخاصة بكتيريا المستديمة النزلية 80.5%، البكتيريا العقدية 72.9% و الإشريكية القولونية 54.5%، كما كان هناك مقاومة عالية لمركب السلفامثيكسازول + الترايبيثوريم من قبل هذه البكتيريا وبالنسب التالية 75.5%، 80.4% و 48.1% لكل منها على التوالي. لقد كانت المقاومة العامة لدواء الجنتاميسين متوسطه (26.0% من 1567) ولكن من المهم ملاحظة ان البكتيريا السالبة بقيت حساسة لهذا الدواء. ومن الجدير ملاحظة ان نحو 24.3% من 839 تم تحليلها لتعدد مقاومتها لمركب الامكسيسلين + الكالونيت ولدواء الجنتاميسين.

الاستنتاجات: إن هذه الدراسة تبين أن نمط مقاومة البكتيريا لمضادات الجراثيم عالية جدا وتندر بالخطر وربما كان ذلك يعكس سوء استعمال هذه المضادات في المنطقة الشرقية من المملكة العربية السعودية.

التوصيات: نوصي بان يكون لكل مستشفى سياسة خاصة تعتمد على التحليل المستمر لنمط مقاومة البكتيريا في المنطقة التي يقع بها، كما نؤكد على أهمية إنشاء مركز في كل منطقة من مناطق المملكة لمكافحة أمراض الأحماج وكذلك لحفظ وتبادل المعلومات وصياغة الاستراتيجية اللازمة لشراء وصرف واستعمال مضادات الجراثيم

الكلمات المرجعية: مضادات الجراثيم ، مقاومة مضادات الجراثيم ، كائنات حية دقيقة ممرضة ، المملكة العربية السعودية.

Correspondence to:

Dr. Mastour Al-Ghamdi, Department of Pharmacology, College of Medicine, King Faisal University, P.O. Box 2114, Dammam 31451, Saudi Arabia

Introduction and Aim: A sharp worldwide rise in bacterial resistance to antimicrobial agents in both nosocomial and community acquired pathogens has recently been observed. This may complicate treatment of infectious disease or increase the cost of its management. It is, therefore, important to regularly investigate the patterns of resistance to antimicrobial agents at both local and national levels.

Methods: The antibiograms of organisms isolated over a one-year period in King Fahd Hospital of the University were analyzed.

Results: Of the 3679 microbial isolates of 35 types of organisms identified, the most common were *Streptococcus* spp (25.5%), *S. aureus* (16.1%), *E. Coli* (12.7%), *Psuedomonas* spp (9.3%) and *Klebsiella* spp (7%) High resistance rates (>50%) to ampicillin and to amoxycillin + clavulanate (AMX+CLV) were encountered in *Enterobacter* spp., and *H. influenzae* while in *E. coli*, the resistance was higher to ampicillin (60.0%) than to AMX+CLV (38.1%). With regard to *S. aureus*, 98.3%, 91.1% and 25.5% of isolates were resistant to penicillin, AMX+CLV and methicillin respectively but all were sensitive to vancomycin. High resistance (53% of 2830 isolates) to tetracycline was also observed especially in *H. influenzae* (80.5%), *Streptococcus* spp (72.9%) and *E. Coli* (54.5%). The same organisms were also highly resistant to trimethoprim/sulphamethoxazole with rates of 75.5%, 80.4% and 48.1% respectively. Moderate resistance (26% of 1567 isolates) to gentamicin was noted but the drug remained very effective against most tested gram-negative organisms. In addition, multiple resistance to gentamicin and AMX+CLV was also detected in 24.3% of 839 isolates.

Conclusions and Recommendations: It is concluded that the alarmingly high pattern of bacterial resistance to antibiotics may reflect the extent of use of each antibiotic in the eastern province of Saudi Arabia. It is recommended that hospital antibiotic policies (purchasing, prescribing and dispensing) be based on, and regularly reviewed in accordance with hospital antibiogram results. A center for infectious disease control should also be established in each region of the Kingdom to disseminate information and coordinate antibiotic policies among hospitals.

Key Words: Antibiotics, resistance, pathogenic organisms, Saudi Arabia

INTRODUCTION

Over the last several years, the incidence of bacterial resistance to antimicrobial agents has risen sharply in both nosocomial and community acquired pathogens.¹ The resistance to antibiotics may result in therapeutic failure, relapse of infections or increase in the cost of their management.² Many factors contribute to the increase in the incidence of bacterial resistance to antibiotics, particularly, the misuse of antibiotics by physicians and the

easy acquisition of antibiotics via non-physicians.³ In addition, the feeding of farm animals with subtherapeutic levels of antimicrobial agents may cause the development of resistant strains that may spread to humans.³

The mechanisms by which bacterial resistance to antibiotics arise may be natural or acquired through chromosomal mutation or transfer of plasmids between bacterial cells by conjugation, transformation and transduction.⁴ Resistance to individual antibiotics differs

according to bacterial species and antibiotic policies adopted by different countries. One of the most important mechanisms of resistance to β -lactam antibiotics is the production of β -lactamase enzymes. The incidence of development of strain-producing enzymes together with that of those with extended spectrum β -lactamases has been increasing rapidly.⁵ Most of these strains show cross-resistance to different types of antibiotics.⁵ Among the isolates which exhibit these characteristics are *E. coli* and *Klebsiella* spp. Resistance to the new fluoroquinolones is also increasing especially in some nosocomial pathogens such as *Serratia* spp., *Acinetobacter* spp., and methicillin-resistant *S. aureus*.⁶

Our study aimed at analyzing the antibiograms of the organisms isolated during a one-year period in the laboratories of King Fahd Hospital of the University, Al-Khobar, in order to provide the basis for updating the current antibiotic policy in our hospital and serve as base data for future review.

METHODOLOGY

The results of all microbiological susceptibility tests performed at King Fahd Hospital of the University (KFHU) were collated over a period of one year, between 1st January 1995 and 31st December 1995. Organisms were isolated and identified according to standard laboratory methods.⁷ Each organism was tested against the recommended antimicrobial agents using single-disc antibiotic-sensitivity testing method. Susceptibility tests were performed using BBL[®] Sensi-Disc[®] antimicrobial susceptibility test discs (Becton Dickinson Microbiology Systems, Cockeysville, USA). The criteria for interpretation were those recommended by the National Committee for Clinical Laboratory

Standards (NCCLS)⁸ and quality control was performed on a regular basis. Control culture of *S. aureus* (ATCC 25923), *E. coli* (ATCC 25922) and *P. aeruginosa* (ATCC 27853) were used and zone diameters were measured in parallel with susceptibility tests performed on clinical isolates. The zone diameters given by the control studies were compared with the standard zone diameters recommended by NCCLS. Patient's number, type of specimen, organism detected and its antibiogram were recorded and later entered in a database for analysis using SPSS/PC software.

RESULTS

Over the one-year period, 3679 isolates of 35 types of organisms were isolated from 2484 patients (Table 1). The most frequently isolated organisms (939 – 25.5%) were streptococcus groups (552 *Streptococcus* B, 199 *Streptococcus* D, 124 *Streptococcus* A, 57 *Streptococcus pneumoniae* and 7 *Viridans streptococci*), *S. aureus* 594 (16.1%), *E. coli* 469 (12.7%) and *Pseudomonas* spp. 342 (9.3%).

The overall resistance rate to ampicillin was 36.4%. *Streptococcus* groups showed the lowest resistance rate (1.6%) while the highest rates were observed with *Enterobacter* spp. (92.8%), *H. influenzae* (61.9%) and *E. coli* (60.2%) (Table 2). *S. aureus*, *Enterobacter* spp., *H. influenzae* and *E. coli* organisms were also highly resistant to amoxicillin + clavulanate with rates of 91.1%, 80%, 50% and 38.1% respectively (Table 3). All *B. fragilis*, 98.3% of *S. aureus* and 92% of *S. epidermidis* isolates were resistant to penicillin G while streptococci remained the most sensitive to the drug with a resistance rate of only 5.6% (Table 4).

The resistance rates of *Pseudomonas* spp., isolates to piperacillin, aztreonam, imipenem and ceftazidime were 8.5%, 16%, 12.4% and 6.8% respectively; 15.2% of 407 *S. aureus* and 25.7% of 74 *S. epidermidis* isolates were resistant to ceftoxitin.

Table 1: Organisms isolated from patients treated in KFHU

Organisms Detected	Frequency	%
Streptococci	939	25.5
S. aureus	594	16.1
E. coli	469	12.7
Pseudomonas spp.	342	9.3
Klebsiella spp.	258	7.0
Candida spp.	172	4.7
Enterobacter spp.	145	3.9
S. epidermidis	119	3.2
Salmonella spp.	118	3.2
H. influenzae	90	2.4
H. aegyptius	80	2.2
Serratia spp.	64	1.7
Proteus spp.	40	1.1
Acinetobacter spp.	39	1.1
Citrobacter spp.	30	0.8
B. fragilis	29	0.8
Peptococcus spp.	21	0.6
S. saprophyticus	19	0.5
M. catarrhalis	17	0.5
M. morgani	17	0.5
Shigella spp.	16	0.4
G. vaginalis	13	0.4
N. gonorrhoeae	12	0.3
Providencia spp.	9	0.2
H. pylori	7	0.2
X. maltophilia	6	0.2
B. melentesis	3	0.1
C. perfringens	2	0.1
Aspergillus spp.	2	0.1
Bacillus spp.	2	0.1
Campylobacter spp.	1	0.0
Corynebacteria spp.	1	0.0
Aeromonas sobria	1	0.0
Flavobacterium spp.	1	0.0
C. tetani	1	0.0
Total	3679	100

Table 2: Patterns of resistance to ampicillin

Microorganisms	No. of tests	No. resistant	% Resistance
E. coli	455	274	60.2
Enterobacter spp.	139	129	92.8
H. aegyptius	72	44	45.8
H. influenzae	84	52	61.9
Salmonella spp.	117	26	22.2
Streptococci	925	15	1.6
Others	315	227	72.1
Total	2107	767	36.4

Table 3: Patterns of resistance to amoxicillin + clavulanate (AMX + CLV)

Micro-organisms	No. of tests	No. Resistant	% Resistant
E. Coli	197	75	38.1
Enterobacter spp	110	88	80.0
H. aegyptius	72	33	45.8
H. influenzae	84	42	50.0
Klebsiella spp	149	36	14.5
Salmonella spp	118	7	5.9
S. aureus	146	133	91.1
Streptococci	412	4	1.0
Others	208	119	57.2
Total	1496	537	35.9

Table 4: Patterns of resistance to penicillin G

Micro-organisms	No. of tests	No. Resistant	% Resistant
B. fragilis	28	28	100
G. vaginalis	13	2	15.4
Peptococcus spp	18	2	11.1
S. aureus	517	508	98.3
S. epidermidis	100	92	92.0
Streptococci	568	32	5.6
Others	67	48	71.6
Total	1311	712	54.3

Table 5: Patterns of resistance to tetracycline

Micro-organisms	No. of tests	No. Resistant	% Resistant
E. Coli	418	228	54.5
Enterobacter spp	131	36	27.5
H. aegyptius	65	50	76.9
H. influenzae	82	66	80.5
Klebsiella spp	130	49	37.8
Salmonella spp	114	24	21.1
S. aureus	507	179	35.3
S. epidermidis	102	29	19.4
Streptococci	872	636	72.9
Others	409	192	46.9
Total	2830	1489	52.3

Table 6: Patterns of resistance to gentamicin and multiple resistance to gentamicin and amoxicillin + clavulanate

Micro-organisms	Resistance to gentamicin		Resistance to gentamicin & AMX+CLV	
	No. tested	No. Resistant (%)	No. tested	No. Resistant (%)
E. Coli	211	38 (18.0)	168	12 (7.10)
Enterobacter spp	120	26 (21.7)	106	20 (18.9)
H. aegyptius	71.0	8 (11.3)	66	3 (4.50)
H. influenzae	69.0	11 (15.9)	63	3 (4.80)
Klebsiella spp	167	27 (16.2)	139	16 (11.5)
Pseudomonas spp	328	60 (18.3)	6	1 (16.7)
S. aureus	239	130 (54.4)	124	110 (88.7)
Others	321	120 (37.4)	167	39 (23.4)
Total	1568	411 (26.2)	839	204 (24.3)

Table 7: Patterns of resistance to trimethoprim/sulphamethoxazole

Micro-organisms	No. of tests	No. Resistant	% Resistant
E. Coli	455	219	48.1
Enterobacter spp	143	28	19.6
H. aegyptius	69	62	89.9
H. influenzae	85	64	75.5
Klebsiella spp	248	64	25.8
Salmonella spp	115	15	13.0
S. aureus	533	111	20.8
S. epidermidis	100	26	26.0
Streptococci	929	742	80.4
Others	295	117	39.7
Total	2972	1448	48.7

Sensitivity of 2830 isolates to tetracycline is presented in Table 5. The overall resistance rate was 52.3%. In ranking order, the higher resistance rates were 80.5%, 76.9%, 72.9% and 54.5% for H. influenzae, H. aegyptius, streptococci and E. coli respectively, while S. epidermidis had the lowest rate of resistance (19.4%).

Table 6 summarizes the resistance patterns of 1568 isolates to gentamicin. The highest rate of resistance (54.4%) was observed with S. aureus and the lowest (11.3%) with H. aegyptius. In addition, a high resistance pattern to amikacin was exhibited by S. aureus, 135 (71.1%) while 33 (10%) of 331 Pseudomonas spp. and

only 1 (1.1%) of 93 S. epidermidis isolates showed resistance to it. All the 146 (25.5%) methicillin resistant S. aureus isolates were sensitive to vancomycin and teicoplanin but 11.3% of them were resistant to lincomycin.

Sensitivity of 2972 isolates to trimethoprim/sulphamethoxazole is shown in Table 7. The overall resistance rate was 48.7%, the highest rate (89.9%) was observed with H. aegyptius, streptococci (80.4%), H. influenzae (75.5%), and E. coli (48.1%) while Salmonella spp. showed the lowest resistance rate (13%).

Nalidixic acid, norfloxacin and nitrofurantoin showed high efficacy against E. coli with resistance rates as low as 15.8%, 10.5% and 7.4% respectively. Only 7 (4.3%) of 163 Klebsiella spp. and 6 (5%) of 119 Enterobacter spp. isolates were resistant to ciprofloxacin.

Amoxicillin + clavulanate and chloramphenicol were the most effective drugs against Salmonella spp. isolates with resistance rates of 5.9% and 8.7% respectively, while resistance rates to erythromycin were relatively high in streptococci (41.5%) and S. aureus (33.9%).

DISCUSSION

The data in this study include community and nosocomial infections at King Fahd Hospital of the University (KFHU) in the eastern province of Saudi Arabia. The most frequently isolated pathogens were strepto-

cocci (25.5%) of which streptococcus B was the most common group, *S. aureus* (16.1%) and *E. coli* (12.7%). However, another study carried out in a general hospital in the same region⁹ showed that the most frequently isolated nosocomial pathogens were *Pseudomonas* spp., *S. aureus*, *Klebsiella* spp., and *E. coli*. Similar patterns of prevalence were observed in Danish, Spanish and Canadian hospitals while *P. aeruginosa* and methicillin resistant coagulase-negative staphylococci and *S. aureus* were found to be the most frequent nosocomial pathogens in some other European hospitals.¹⁰⁻¹⁴

The antibiograms of isolated organisms showed great variation between types of antimicrobial agents tested and types of isolates. Very low rates of resistance were observed with streptococci to all the investigated penicillins (range 1.0-5.6%), thus penicillins remain the most effective agents in the treatment of streptococcal infections which constitute 26% of all infections. In contrast, very high rates of resistance (>90%) were encountered with *S. aureus* to both penicillin and AMX+CLV suggesting that the likely mechanism of resistance to penicillin and AMX+CLV is in the change in the target of action of penicillin and not the production of beta-lactamases since AMX+CLV contains a beta lactamase inhibitor, clavulanic acid. Similarly, enterobacter isolates in our hospital were highly resistant to both ampicillin (92.8%) and AMX+CLV (80.0%), again, suggesting that the mechanism of enterobacter resistance to beta lactam antibiotics is not via the production of β -lactamase. These results are in agreement with those of Andersen et al¹⁵ who reported that 46 enterobacter isolates showed a high resistance to both extended spectrum penicillins and third generation

cephalosporins. Resistance of *E. coli* to ampicillin (60.2%) and AMX+CLV (38.1%), however, suggests that production of β -lactamase and extended – spectrum β -lactamase are the most likely mechanisms of resistance by these organisms. Similar findings have been reported for both *E. coli* and *Klebsiella* spp., by several investigators.^{5,16-18}

Resistance to tetracycline (Table 5) was generally high or moderate with all isolated organisms including *Haemophilus* spp., streptococci, *E. coli* and staphylococci. However, tetracyclines are not considered among the drugs of choice for infections caused by all of these organisms. Nevertheless, our data reflects the impact of extensive use of these antibiotics in primary health clinics and as additives to animal feed in the eastern province of Saudi Arabia. It is well established that cross-resistance between the various tetracycline compounds is common and probably plasmid mediated. The mechanisms by which organisms acquire resistance to tetracyclines possibly involve decreased drug penetration through cell membranes, reduced binding to bacterial ribosomes or by enzymatic inactivation of the drug.¹⁹

The good activity of gentamicin against all gram-negative organisms investigated (Table 6) in our study confirms the fact that aminoglycosides are known to be mostly effective against gram negative species. The relatively low resistance rates observed with gentamicin suggest that aminoglycosides are not misused since their use is restricted mainly to hospitalized patients. Multiple resistance to both gentamicin and AMX+CLV was observed with some gram-negative organisms, such as *E. coli* (7.1%), *Enterobacter* spp., (18.9%) and *Klebsiella* spp., (11.5%). Such findings were previously reported by French et al¹⁸ who isolated an extended-spectrum β -lactamase producing *Klebsiella* strains which were resistant to

aminoglycosides and both cephalosporins and β -lactam β -lactamase inhibitor combinations. Although, *P. aeruginosa* isolates were not investigated for the combination of aminoglycosides and extended spectrum β -lactams in our study, other investigators reported an outbreak of these organisms which were highly resistant to aminoglycosides, extended spectrum β -lactams and quinolones in a Brazilian hospital.²⁰

Trimethoprim is a bacteriostatic agent commonly used in combination with sulphamethoxazole (Co-trimoxazole, TMP-SMX) or as a single agent to treat urinary tract infections.²¹⁻²³ Our data suggest an emergence of high resistance to this drug combination especially, in *E. coli* and streptococci which are the main infecting agents of the urinary tract. The mechanism of acquired resistance to trimethoprim in gram negative bacteria is suggested to be plasmid – mediated alteration of the target enzyme, dihydrofolate reductase.²⁴

In contrast to the observation of Asensi et al²⁵ who reported an outbreak in Brazil of *Salmonella agona* that was resistant to ampicillin, TMP-SMX, tetracycline, chloramphenicol, cephalosporins and aminoglycosides. Amoxicillin + clavulanate, chloramphenicol and trimethoprim were still highly effective against *Salmonella* spp.

The results of the investigated quinolones showed that nalidixic acid and norfloxacin had good activity against *E. coli* while ciprofloxacin was highly effective against enterobacteriaceae. Similar results were reported by Acar et al⁶ who concluded that resistance to fluoroquinolones was still rare in common pathogens in France.

In conclusion, the antibiograms of pathogenic organisms in the eastern province of Saudi Arabia show alarmingly

high resistance patterns especially to these essential antibiotics. This may be due to the fact that these drugs are available to patients without prescription^{26,27} inspite of laws which classify them as non-over-the-counter (non-OTC) drugs. However, in comparison to those published in other countries our results show a great variation owing to a number of factors, such as antibiotic policies, the extent of use of broad spectrum antibiotics, abuse of antibiotics and the absence of global standard method for performing the sensitivity test or interpreting the results.²⁸

We, therefore, recommend that antibiogram studies of nosocomial and community pathogens should be carried out periodically on national or regional levels. The results would be of great value in optimizing treatment strategies and national drug policies as well as in measuring the success of these policies. Furthermore, the results of such studies could be used to educate policy-makers, prescribers, health care professionals, and the general public in order to reduce misuse of antimicrobial agents.

ACKNOWLEDGMENTS

The King Abdulaziz City of Science and Technology (KACST) to whom we express our gratitude funded this work. Our sincere thanks also go to Dr. Abdulrahman Qurashi, and the technical staff at the Microbiology laboratories at King Fahd Hospital of the University and to Mr. Hasan Isa and Mr. Abdul-Rahman Al-Fakki, College of Medicine for their assistance. We also thank Dr. E.B. Larbi for reviewing the manuscript.

REFERENCES

1. Dever LA, Dermody TS. Mechanisms of bacterial resistance to antibiotics. *Arch Intern Med* 1991; 151: 886-95.
2. Sanders CC, Sonders WE. Microbial resistance to newer generation B-lactam antibiotics. Clinical and laboratory implications. *J Infect Dis* 1985; 151:399-406.
3. Boyed RF, Hoerl BG. Basic medical microbiology 4th ed. Boston (Toronto): Little Brown and Company; 1991.

4. Livemore DM, Wood MJ. Mechanisms of bacterial resistance to antimicrobial agents. *N Engl J Med* 1991; 324: 601-12.
5. Sader HS, Pfaller MA, Jones RN. Prevalence of important pathogens and the antimicrobial activity of parenteral drugs at numerous medical centers in the United States. II study of beta-lactamases producing Enterobacteriaceae. *Diagn-Microbiol-Infect Dis* 1994; 20(4):203-8.
6. Acar JF, O' Brien TF, Goldstein FW, Jones RN. The epidemiology of bacterial resistance to quinolones. *Drugs* 1993; 45 (suppl. 3): 24-8.
7. Koneman EW, Allen SD, Janda WM, Schreckenberger BC, Winns WC. *Color Atlas and Textbook of Diagnostic Microbiology*. Philadelphia: J.B. Lippincott Company; 1992.
8. National Committee for Clinical Laboratory Standards (NCCLS). *Performance Standards for Antimicrobial Disk Susceptibility Tests*. 5th ed. Approved standard M2 - A5. Villanova, Pa: National Committee for Clinical Laboratory Standards; 1993.
9. Elbashier AM. Five years of prospective surveillance of nosocomial infections in a Saudi Arabian general hospital. *Saudi Med J* 1997; 18(4): 414-7.
10. Fomsgaard A, Hoiby N, Fris HM, Gahrn-Hansen B, Kolmos HJ, chouenborg P, Korsager B, Tvede M, Gutschik E and Bremmelgaard A. Prevalence and antibiotic sensitivity of Danish versus other European bacterial isolates from intensive care and hematology/oncology units. *Eur J Clin Microbiol Infect Dis* 1995; 14(4): 275-81.
11. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, Wolff M, Spencer RC, Hemmer M. The prevalence of nosocomial infection in intensive care units in Europe. *JAMA*. 1995; 274(8): 639-44.
12. Spencer RC. Epidemiology of infection in ICUs. *Intensive Care Med* 1994; 20 (suppl 4): S2-6.
13. Vazques F, Mendoza MC, Villar MH, Perez F and Mendez FJ. Survey of bacteraemia in a Spanish hospital over a decade (1981-1990). *J Hosp Infect* 1994; 26(2): 111-21.
14. Preston CA, Bruce AW and Reid G. Antibiotic resistance of urinary pathogens isolated from patients attending the Toronto Hospital between 1986 and 1990. *J Hosp Infect* 1992; 22(2):129-35.
15. Anderson J, Asmar BI and Dajani AS. Increasing Enterobacter bacteremia in pediatric patients. *Pediatr-Infect-Dis J* 1994; 13(9): 787-92.
16. Johnson AP, Weinbren MJ, Ayling-Smith B, Du-Bois-SK, Amyes SG, George-RC. Outbreak of infection in two UK hospitals caused by a strain of klebsiella pneumoniae resistant to cefotaxime and ceftazidime. *J Hosp Infect* 1992; 20(2):97-103.
17. Meyer-KS, Urban C, Eagan JA, Berger BJ and Rahal JJ. Nosocomial outbreak of klebsiella infection resistant to late-generation cephalosporins. *Ann Intern Med* 1993; 119(5): 353-8.
18. French GL, Shannon Kpand Simmons N. Hospital outbreak of Klebsiella pneumoniae resistant to broad-spectrum cephalosporins and beta lactam-beta-lactamase inhibitor combinations by hyperproduction of SHV-5 beta-lactamase. *J Clin Microbiol* 1996; 34(2):358-63.
19. Speer, B.S., Shoemaker, N.B and Salyers, A.A. Bacterial resistance to tetracycline: mechanism, transfer, and clinical significance. *Clin Microbiol Rev* 1992; 5:387-99.
20. Sader-HS, Pignatari AC, Leme IL, Burattini MN, Tancredi R, Hollis RJ and Jones RN. Epidemiologic typing of multiply drug-resistant pseudomonas aeruginosa isolated from an outbreak in an intensive care unit. *Diagn Microbiol Infect Dis* 1993; 17(1): 13-8.
21. Vahlensieck W Jr and Westenfelder M. Nitrofurantoin versus trimethoprim for low-dose long-term prophylaxis in patients with recurrent urinary tract infections. *Int Urol Nephrol* 1992; 24 (1): 3-10.
22. Spencer RC; Moseley DJ and Greensmith MJ. Nitrofurantoin modified release versus trimethoprim or co-trimoxazole in the treatment of uncomplicated urinary tract infections in general practice. *J Antimicrob Chemother* 1994; 33 suppl A: 121-9.
23. Masterton RG and Bochsler JA. High-dosage co-amoxiclav in a single dose versus 7 days of co-trimoxazole as treatment of uncomplicated lower urinary tract infection in women. *J Antimicrob Chemother* 1995; 35(1):129-37.
24. Houvinen, P. Trimethoprim resistance. *Antimicrob Agents Chemother* 1987;31:1451-6.
25. Asensi MD, Solari CA and Hofer E. A salmonella agona outbreak in a pediatric hospital in the city of Rio de Janeiro, Brazil *Mem Inst Oswaldo Cruz* 1994; 89(1):1-4.
26. Al-Freihi H, Ballal SG, Jaccarini A, Young MS, Abdul-Cader Z, El-Mouzan M. Potential for drug misuse in the eastern province of Saudi Arabia. *Ann Saudi Med* 1987; 7:301-5.
27. Bawazir SA. Prescribing pattern at community pharmacies in Saudi Arabia. *Int. Pharmacy J* 1992; 6 (5): 222-3.
28. World Health Organisation, Geneva. *Weekly Epidemiological Record* 1997; 72 (45): 333-40.